Two patients died of sepsis in a Phase II trial of Progenics Pharmaceuticals’ in-development prostate cancer treatment, spurring concern that the drug is too toxic to merit further study and sending the biotech’s shares down as much as 30%.

…read more

Source: Progenics tanks after two trial deaths cast doubt on its lead program


0 No comments